A Multi-center, Randomized, Subject Blind, Active Controlled Design Clinical Study to Evaluate the Efficacy and Safety of Volus as Compared to PowerFill® for Temporary Penile Enhancement
Launched by HUGEL · Jul 13, 2016
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Male subjects aged above 20 and below 65. (20≤male≥65)
- • 2. be rating himself, when screening, as "Small or Very Small" on Self-Questioned Questionnaire ( SQQ) including the question: " How do you rate your penile size? // Very small, Small, Normal, Big, Very Big?"
- • 3. During the study period, subjects will not received any treatments associated with penile enhancement.
- • 4. Subjects will sign an informed consent form
- Exclusion Criteria:
- • 1. Prior treatment for penile enhancement (e.g. fat, dermal graft).
- • 2. Subjects who have penile malformation (e.g. Peyronie's disease), which can make impossible to perform the intervention
- • 3. Allergic to hyalluronic acid.
- • 4. Inflammatory or/and infectious disease on penis that can affect on this study
About Hugel
Hugel is a leading biopharmaceutical company focused on the development and commercialization of innovative aesthetic and therapeutic solutions. With a commitment to advancing healthcare, Hugel specializes in the production of high-quality injectable products, including botulinum toxin and dermal fillers, designed to enhance patient outcomes in aesthetic medicine. The company adheres to rigorous standards of safety and efficacy, conducting comprehensive clinical trials to ensure that its products meet the highest regulatory requirements. Through continuous research and development, Hugel aims to expand its portfolio and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials